Aceragen (ACGN) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 15, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'IDRA	'
Entity Registrant Name	'IDERA PHARMACEUTICALS, INC.	'
Entity Central Index Key	'0000861838	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	85,810,683

Condensed_Balance_Sheets_Unaud

Condensed Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$48,491	$26,278
Short-term investments	9,789	3,125
Prepaid expenses and other current assets	1,102	874
Total current assets	59,382	30,277
Long-term investments	'	6,189
Property and equipment, net	926	90
Restricted cash and other assets	324	311
Total assets	60,632	36,867
Current liabilities:	'	'
Accounts payable	2,064	904
Accrued expenses	4,616	3,506
Current portion of note payable	59	'
Total current liabilities	6,739	4,410
Note payable, net of current portion	804	'
Other liabilities	268	5
Total liabilities	7,811	4,415
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value, Authorized - 5,000 shares	0	0
Common stock, $0.001 par value, Authorized - 280,000 shares; Issued and outstanding - 85,802 and 66,252 shares at September 30, 2014 and December 31, 2013, respectively	86	66
Additional paid-in capital	486,817	434,285
Accumulated deficit	-439,608	-412,884
Accumulated other comprehensive loss	-2	-7
Total stockholders' equity	52,821	32,452
Total liabilities and stockholders' equity	60,632	36,867
Series E preferred stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value	5,528	5,528
Series D preferred stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value	'	5,464
Series A preferred stock [Member]	'	'
Stockholders' equity:	'	'
Preferred stock, $0.01 par value	$0	$0

Condensed_Balance_Sheets_Unaud1

Condensed Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	280,000,000	280,000,000
Common stock, shares issued	85,802,000	66,252,000
Common stock, shares outstanding	85,802,000	66,252,000
Series E preferred stock [Member]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares designated	424,000	424,000
Preferred stock, shares issued	424,000	424,000
Preferred stock, shares outstanding	424,000	424,000
Series D preferred stock [Member]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares designated	0	1,124,000
Preferred stock, shares issued	0	1,124,000
Preferred stock, shares outstanding	0	1,124,000
Series A preferred stock [Member]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares designated	1,500,000	1,500,000
Preferred stock, shares issued	1,000	1,000
Preferred stock, shares outstanding	1,000	1,000

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Alliance revenue	$30	$7	$71	$43
Operating expenses:	'	'	'	'
Research and development	6,678	2,510	19,248	6,835
General and administrative	2,873	2,179	7,646	5,305
Total operating expenses	9,551	4,689	26,894	12,140
Loss from operations	-9,521	-4,682	-26,823	-12,097
Other income (expense):	'	'	'	'
Investment income, net	14	2	45	6
Foreign currency exchange gain (loss)	52	-58	54	-45
Net loss	-9,455	-4,738	-26,724	-12,136
Loss on extinguishment of convertible preferred stock and preferred stock dividends	119	278	422	2,587
Net loss applicable to common stockholders	-9,574	-5,016	-27,146	-14,723
Basic and diluted net loss per common share applicable to common stockholders (Note 13)	($0.11)	($0.11)	($0.33)	($0.40)
Shares used in computing basic and diluted net loss per common share applicable to common stockholders	84,527	45,720	81,200	37,203
Net loss	-9,455	-4,738	-26,724	-12,136
Other comprehensive (loss) gain:	'	'	'	'
Unrealized (loss) gain on available-for-sale securities	-5	'	5	'
Comprehensive loss	($9,460)	($4,738)	($26,719)	($12,136)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities:	'	'
Net loss	($26,724)	($12,136)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Stock-based compensation	2,086	994
Depreciation and amortization expense	135	106
Amortization of investment premiums	149	'
Issuance of common stock for services rendered	62	18
Other	-8	41
Changes in operating assets and liabilities:	'	'
Prepaid expenses and other current assets	-228	-199
Accounts payable, accrued expenses, and other liabilities	2,718	-1,499
Net cash used in operating activities	-21,810	-12,675
Cash Flows from Investing Activities:	'	'
Purchases of available-for-sale securities	-2,619	'
Maturities of available-for-sale securities	2,000	'
Purchases of property and equipment	-891	-4
Net cash used in investing activities	-1,510	-4
Cash Flows from Financing Activities:	'	'
Proceeds from equity financings	37,137	40,538
Proceeds from issuance of note payable	850	'
Dividends paid	-582	-1,067
Proceeds from exercise of common stock warrants and options and employee stock purchases	8,132	1,864
Payments on capital lease	-4	-3
Net cash provided by financing activities	45,533	41,332
Net increase in cash and cash equivalents	22,213	28,653
Cash and cash equivalents, beginning of period	26,278	10,096
Cash and cash equivalents, end of period	$48,491	$38,749

Organization

Organization	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Organization	'
	(1) Organization
	Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare diseases. The Company’s lead drug candidate is IMO-8400, a novel synthetic oligonucleotide antagonist of TLR7, TLR8 and TLR9. IMO-8400 is in development for the treatment of certain genetically defined forms of B-cell lymphoma and for the treatment of selected rare autoimmune diseases. The Company previously completed a Phase 1 clinical trial of IMO-8400 in healthy subjects and a Phase 2 proof-of-concept clinical trial in patients with moderate to severe plaque psoriasis.
	Idera is currently conducting a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström’s macroglobulinemia and Phase 1/2 clinical trial of IMO-8400 in patients with diffuse large B-cell lymphoma (“DLBCL”), who harbor the MYD88 L265P oncogenic mutation. The Company is also evaluating the potential application of TLR antagonism in rare diseases such as dermatomyositis, a rare debilitating autoimmune disease, as well as Duchenne muscular dystrophy (“DMD”) and potentially other indications. The Company believes it can develop and commercialize therapies on its own in these disease indications, which are characterized by small, well-defined patient populations with serious unmet medical needs.
	The Company is also advancing a second novel synthetic oligonucleotide antagonist of TLR7, TLR8 and TLR 9, IMO-9200, as a drug candidate for potential use in selected autoimmune disease indications. The Company initiated patient dosing in a Phase 1 clinical trial of IMO-9200 in healthy volunteers in October 2014 and plans to select a lead indication for further development of this drug candidate in the first half of 2015. Idera is also developing gene silencing oligonucleotides (“GSOs”), a third generation antisense technology designed to inhibit the production of disease-associated proteins. The Company believes this technology may offer significant advantages over other currently practiced antisense and RNA interference (“RNAi”) technologies.
	At September 30, 2014, the Company had an accumulated deficit of $439,608,000. The Company expects to incur substantial operating losses in future periods. The Company does not expect to generate significant product revenue, sales-based milestones or royalties until the Company successfully completes development and obtains marketing approval for drug candidates, either alone or in collaborations with third parties, which the Company expects will take a number of years. In order to commercialize its drug candidates, the Company needs to complete clinical development and comply with comprehensive regulatory requirements.
	The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of clinical trial outcomes, uncertainty of additional funding, and history of operating losses.

New_Accounting_Pronouncements_

New Accounting Pronouncements - Recently Issued	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
New Accounting Pronouncements - Recently Issued	'
	(2) New Accounting Pronouncements — Recently Issued
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08 — Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this ASU require that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s operations and financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosure requirements for individually significant components that do not qualify as discontinued operations. This ASU will be effective prospectively for fiscal years beginning on or after December 15, 2014. Early adoption is permitted, but only for disposals that have not been previously reported in financial statements previously issued. The Company does not expect the adoption of this ASU to have a material effect on its financial statements.
	In May 2014, the FASB issued ASU No. 2014-09 — Revenue from Contracts with Customers (Topic 606). This ASU requires an entity to recognize revenue from the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In particular, this ASU addresses contracts with more than one performance obligation, as well as the accounting for some costs to obtain or fulfill a contract with a customer, and provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. This ASU will be effective for fiscal years beginning after December 15, 2016. Early adoption of this ASU is not permitted. The Company is currently evaluating the effect that the adoption of this ASU will have on its financial statements.

Unaudited_Interim_Financial_St

Unaudited Interim Financial Statements	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Unaudited Interim Financial Statements	'
	(3) Unaudited Interim Financial Statements
	The accompanying unaudited financial statements included herein have been prepared by the Company in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting of normal recurring adjustments, and disclosures considered necessary for a fair presentation of interim period results have been included. Interim results for the nine months ended September 30, 2014 are not necessarily indicative of results that may be expected for the year ended December 31, 2014. For further information, refer to the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on March 13, 2014.

Financial_Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2014
Investments, All Other Investments [Abstract]	'
Financial Instruments	'
	(4) Financial Instruments
	The fair value of the Company’s financial instruments is determined and disclosed in accordance with the three-tier fair value hierarchy specified in Note 6, “Fair Value of Assets and Liabilities.” The Company is required to disclose the estimated fair values of its financial instruments. The Company’s financial instruments consist of cash, cash equivalents, available-for-sale investments and receivables. The estimated fair values of these financial instruments approximate their carrying values as of September 30, 2014 and December 31, 2013. As of September 30, 2014 and December 31, 2013, the Company did not have any derivatives, hedging instruments or other similar financial instruments except for the Company’s Series E convertible preferred stock (the “Series E preferred stock”), the embedded features of which are discussed in Note 8(g) to the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and the Company’s Note Agreement, which is discussed in Note 16, including put and call features which the Company determined are clearly and closely associated with the debt host and do not require bifurcation as a derivative liability, or the fair value of the feature is immaterial.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents	'
	(5) Cash and Cash Equivalents
	The Company considers all highly liquid investments with maturities of 90 days or less when purchased to be cash equivalents. Cash and cash equivalents at September 30, 2014 and December 31, 2013 consisted of cash and money market funds.

Fair_Value_of_Assets_and_Liabi

Fair Value of Assets and Liabilities	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Assets and Liabilities	'
	(6) Fair Value of Assets and Liabilities
	The Company measures fair value at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using assumptions that market participants would use in pricing the asset or liability (the “inputs”) into a three-tier fair value hierarchy. This fair value hierarchy gives the highest priority (Level 1) to quoted prices in active markets for identical assets or liabilities and the lowest priority (Level 3) to unobservable inputs in which little or no market data exists, requiring companies to develop their own assumptions. Observable inputs that do not meet the criteria of Level 1, and include quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets and liabilities in markets that are not active, are categorized as Level 2. Level 3 inputs are those that reflect the Company’s estimates about the assumptions market participants would use in pricing the asset or liability, based on the best information available in the circumstances. Valuation techniques for assets and liabilities measured using Level 3 inputs may include unobservable inputs such as projections, estimates and management’s interpretation of current market data. These unobservable Level 3 inputs are only utilized to the extent that observable inputs are not available or cost-effective to obtain. The Company applies ASU No. 2011-04, “Fair Value Measurement (Topic 820),” in its fair value measurements and disclosures.
	The table below presents the assets and liabilities measured and recorded in the financial statements at fair value on a recurring basis at September 30, 2014 and December 31, 2013 categorized by the level of inputs used in the valuation of each asset and liability.
	(In thousands)	Total		Quoted Prices		Significant		Significant
				in Active		Other		Unobservable
				Markets		Observable		Inputs
				for Identical		Inputs		(Level 3)
				Assets or		(Level 2)
				Liabilities
				(Level 1)
	September 30, 2014
	Assets
	Money market funds	$	47,181	$	47,181	$	—	$	—
	Short-term investments — commercial paper		999		—		999		—
	Short-term investments — corporate bonds		8,790		—		8,790		—
	Total Assets	$	56,970	$	47,181	$	9,789	$	—
	(In thousands)	Total		Quoted Prices		Significant		Significant
				in Active		Other		Unobservable
				Markets		Observable		Inputs
				for Identical		Inputs		(Level 3)
				Assets or		(Level 2)
				Liabilities
				(Level 1)
	December 31, 2013
	Assets
	Money market funds	$	25,201	$	25,201	$	—	$	—
	Short-term investments — commercial paper		1,997		—		1,997		—
	Short-term investments — corporate bonds		1,128		—		1,128		—
	Long-term investments — corporate bonds		6,189		—		6,189		—
	Total Assets	$	34,515	$	25,201	$	9,314	$	—
	The Level 1 assets consist of money market funds, which are actively traded daily. The Level 2 assets consist of corporate bond and commercial paper investments whose fair value may not represent actual transactions of identical securities. The fair value of corporate bonds is generally determined from quoted market prices received from pricing services based upon quoted prices from active markets and/or other significant observable market transactions at fair value. The fair value of commercial paper is generally determined based on the relationship between the investment’s discount rate and the discount rates of the same issuer’s commercial paper available in the market which may not be actively traded daily. Since these fair values may not be based upon actual transactions of identical securities, they are classified as Level 2. Since any investments are classified as available-for-sale securities, any unrealized gains or losses are recorded in accumulated other comprehensive gain (loss) or within stockholders’ equity on the balance sheets. The Company did not elect to measure any other financial assets or liabilities at fair value at September 30, 2014 or December 31, 2013.

Investments

Investments	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Investments	'
	(7) Investments
	The Company’s available-for-sale investments at fair value consisted of the following at September 30, 2014 and December 31, 2013:
		September 30, 2014
		Cost		Gross			Gross		Estimated
				Unrealized			Unrealized		Fair Value
				(Losses)			Gains
		(In thousands)
	Short-term investments — commercial paper	$	999	$	—		$	—	$	999
	Short-term investments — corporate bonds		8,792		(3	)		1		8,790
	Total investments	$	9,791	$	(3	)	$	1	$	9,789
		December 31, 2013
		Cost		Gross			Gross		Estimated
				Unrealized			Unrealized		Fair Value
				(Losses)			Gains
		(In thousands)
	Short-term investments — commercial paper	$	1,997	$	—		$	—	$	1,997
	Short-term investments — corporate bonds		1,128		—			—		1,128
	Total short-term investments		3,125		—			—		3,125
	Long-term investments — corporate bonds		6,196		(7	)		—		6,189
	Total investments	$	9,321	$	(7	)	$	—	$	9,314
	The Company had no realized gains or losses from available-for-sale securities in the nine months ended September 30, 2014 and 2013. There were no losses or other-than-temporary declines in value included in “Investment income, net” on the Company’s condensed statements of operations and comprehensive loss for any securities for the three and nine months ended September 30, 2014 and 2013. The Company had no auction rate securities as of September 30, 2014 and December 31, 2013. See Note 4, “Financial Instruments,” and Note 6, “Fair Value of Assets and Liabilities” for additional information related to the Company’s investments.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	(8) Property and Equipment
	At September 30, 2014 and December 31, 2013, net property and equipment at cost consisted of the following:
	(In thousands)	September 30,		December 31,
		2014		2013
	Leasehold improvements	$	525	$	525
	Laboratory equipment and other		3,536		2,854
	Total property and equipment, at cost		4,061		3,379
	Less: accumulated depreciation		3,135		3,289
	Property and equipment, net	$	926	$	90
	Depreciation and amortization expense was approximately $57,000 and $31,000 in the three months ended September 30, 2014 and 2013, respectively, and approximately $135,000 and $106,000 in the nine months ended September 30, 2014 and 2013, respectively.

Restricted_Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Restricted Cash	'
	(9) Restricted Cash
	As part of the Company’s lease arrangement for its office and laboratory facility, the Company is required to restrict cash held in a certificate of deposit securing a line of credit for the lessor. As of September 30, 2014 and December 31, 2013, the restricted cash amounted to $311,000 held in certificates of deposit securing a line of credit for the lessor.

Collaborations

Collaborations	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborations	'
	(10) Collaborations
	(a) Collaboration with Abbott Molecular Inc.
	In May 2014, the Company entered into a collaboration with Abbott Molecular, Inc. (“Abbott Molecular”) for the development of a companion diagnostic that can be used to identify patients with the MYD88 L265P oncogenic mutation. Under the agreement, Abbott Molecular has agreed to develop the companion diagnostic to comply with the requirements of the U.S. Food and Drug Administration (“FDA”) Center for Devices and Radiological Health. The Company expects to pay approximately $6,700,000 in external development expenses over five years under the agreement to develop an assay as the prototype of the companion diagnostic, to validate the prototype during its ongoing Phase 1/2 clinical trial of IMO-8400 in patients with DLBCL, and to complete FDA regulatory requirements and launch activities of the final version of the companion diagnostic. Such expenses are subject to increase if Abbott Molecular incurs additional expenses in order to meet unexpected material requirements or obligations not included in the agreement or if the Company is required to conduct additional or different clinical trials which result in Abbott Molecular incurring additional costs. The Company will not receive any revenues from future sales, if any, of the companion diagnostic. The Company expects to use the prototype companion diagnostic developed by Abbott Molecular in its ongoing Phase 1/2 clinical trial of IMO-8400 in patients with DLBCL and in future clinical trials of IMO-8400 in which it needs to identify patients with the MYD88 L265P oncogenic mutation. The Company incurred $1,808,000 in expenses under the Abbott Molecular agreement through September 30, 2014.
	(b) Amendment to Exclusive License and Research Collaboration Agreement with Merck Sharp & Dohme Corp.
	In April 2014, the Company entered into an amendment to its exclusive license and research collaboration agreement with Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc. (“Merck & Co.”)). Under the license and research collaboration agreement, which the Company entered into with Merck & Co. in December 2006, the Company had granted Merck & Co. worldwide exclusive rights to its TLR7, TLR8, and TLR9 agonists for use in combination with Merck & Co.’s therapeutic and prophylactic vaccines under development in the fields of cancer, infectious diseases, and Alzheimer’s disease. As a result of this amendment, Merck & Co.’s rights under the license and research collaboration agreement have been limited to specified TLR7, TLR8, and TLR9 agonists that Merck & Co. selected in January 2012, and the Company regained the rights to pursue its other independently discovered TLR7, TLR8, and TLR9 agonists for use as vaccine adjuvants in the fields of cancer, infectious diseases and Alzheimer’s disease so that it now has the right to pursue its TLR7, TLR8, and TLR9 agonists for use as vaccine adjuvants in all fields. Merck & Co.’s obligations under the agreement to pay the Company milestone payments and royalties continue in effect with respect to the specified TLR7, TLR8, and TLR9 agonists. However, in connection with this amendment, the Company agreed that, to the extent that the Company licenses to third parties any TLR7, TLR8, and TLR9 agonists for use as vaccine adjuvants in the fields of cancer, infectious diseases and Alzheimer’s disease and receives income under such licenses, Merck & Co. may credit against any milestone payments and royalties it owes to the Company an amount equal to 15% of the license income received by the Company under the third-party licenses, up to a maximum of $60.0 million in credits.

Comprehensive_Income_Loss

Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Comprehensive Income (Loss)	'
	(11) Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive loss for the nine months ended September 30, 2014 and 2013 is comprised of reported net loss and any change in net unrealized gains and losses on investments during each period, which is included in accumulated other comprehensive gain (loss) on the accompanying balance sheets. The Company applies ASU No. 2011-05, “Comprehensive Income” by presenting the components of net income and other comprehensive income as one continuous statement.
	The following table includes the changes in the accumulated balance of the component of other comprehensive gain (loss) for the nine months ended September 30, 2014:
	(In thousands)	Nine Months
		ended September 30,
		2014
	Accumulated unrealized loss on available-for-sale securities at beginning of period	$	(7	)
	Change during the period		5
	Accumulated unrealized loss on available-for-sale securities at end of period	$	(2	)
	There was no accumulated unrealized gain or loss on available-for-sale securities during the nine months ended September 30, 2013.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	(12) Stock-Based Compensation
	The Company recognizes all share-based payments to employees and directors as expense in the statements of operations and comprehensive loss based on their fair values. The Company records compensation expense over an award’s requisite service period, or vesting period, based on the award’s fair value at the date of grant. The Company’s policy is to charge the fair value of stock options as an expense, adjusted for forfeitures, on a straight-line basis over the vesting period, which is generally four years for employees and three years for directors.
	The Company recorded charges of $766,000 and $476,000 in its statements of operations and comprehensive loss for the three months ended September 30, 2014 and 2013, respectively, and $2,086,000 and $994,000 in its statements of operations and comprehensive loss for the nine months ended September 30, 2014 and 2013, respectively, for stock-based compensation expense attributable to share-based payments made to employees and directors. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions apply to the options to purchase 2,518,500 and 3,130,083 shares of common stock granted to employees and directors during the nine months ended September 30, 2014 and 2013, respectively:
		Nine Months Ended
		September 30,
		2014			2013
	Average risk free interest rate		1.6	%		1.3	%
	Expected dividend yield		—			—
	Expected lives (years)		4.8			5.2
	Expected volatility		83	%		62	%
	Weighted average grant date fair value of options granted during the period (per share)	$	2.47		$	0.49
	Weighted average exercise price of options granted during the period (per share)	$	3.8		$	0.92
	The expected lives and the expected volatility of the options granted during the nine months ended September 30, 2014 and 2013 are based on historical experience. All options granted during the nine months ended September 30, 2014 and 2013 were granted at exercise prices equal to the fair market value of the common stock on the dates of grant.

Net_Loss_per_Common_Share_Appl

Net Loss per Common Share Applicable to Common Stockholders	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss per Common Share Applicable to Common Stockholders	'
	(13) Net Loss per Common Share Applicable to Common Stockholders
	For the three and nine months ended September 30, 2014 and 2013, basic and diluted net loss per common share applicable to common stockholders is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share applicable to common stockholders is the same as basic net loss per common share applicable to common stockholders as the effects of the Company’s potential common stock equivalents are antidilutive. Total antidilutive securities were 78,349,485 and 87,624,124 for the nine months ended September 30, 2014 and 2013, respectively, and consist of stock options, preferred stock and warrants.
	For the three months ended September 30, 2014, net loss per common share applicable to common stockholders reflects $119,000 in dividends accrued on shares of the Series E preferred stock. For the nine months ended September 30, 2014, net loss per common share applicable to common stockholders reflects $422,000 in dividends accrued on shares of the Company’s Series D convertible preferred stock (“Series D preferred stock”) and the Series E preferred stock. As discussed in Note 15, “Related Party Transactions,” the Series D preferred stock was converted to common stock on February 6, 2014.
	For the three and nine months ended September 30, 2013, net loss per common share applicable to common stockholders reflects $278,000 and $837,000, respectively, in dividends payable on shares of Series D preferred stock and Series E preferred stock. For the nine months ended September 30, 2013, net loss per common share applicable to common stockholders also reflects $1,750,000 related to the loss on extinguishment of the Series D preferred stock and the Series E preferred stock that the Company issued in November 2011 and November 2012, respectively, that has been charged to net loss applicable to common stockholders as a preferred stock dividend. The $1,750,000 loss on extinguishment of the Series D preferred stock and the Series E preferred stock in the nine months ended September 30, 2013 was recorded following the irrevocable waiver by the holder of the Series D preferred stock of the Series D preferred stock redemption rights and liquidation preferences and by the holders of the Series E preferred stock of the Series E preferred stock liquidation preferences, which irrevocable waivers became effective when the Company completed its follow-on underwritten public offering on May 7, 2013. The Company determined that the irrevocable waivers represented changes to the fundamental terms of both the Series D preferred stock and the Series E preferred stock and therefore accounted for them as an extinguishment of the Series D preferred stock and the Series E preferred stock.

Common_Stock_Warrant_and_Optio

Common Stock Warrant and Option Exercises and Employee Stock Purchases	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Common Stock Warrant and Option Exercises and Employee Stock Purchases	'
	(14) Common Stock Warrant and Option Exercises and Employee Stock Purchases
	During the nine months ended September 30, 2014, the Company issued 5,398,609 shares of common stock in connection with purchases under the Company’s 1995 Employee Stock Purchase Plan (the “ESPP”) and warrant and stock option exercises, which resulted in total proceeds to the Company of $8,132,000.
	During the nine months ended September 30, 2013, the Company issued 3,780,945 shares of common stock in connection with employee stock purchases under the ESPP and warrant and stock option exercises, which resulted in total proceeds to the Company of $1,864,000.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	(15) Related Party Transactions
	February 6, 2014 Conversion of Series D Preferred Stock
	On January 10, 2014, the Company notified Pillar Pharmaceuticals I, L.P. (“Pillar I”), an investment partnership managed by one of the Company’s directors and significant stockholders and the holder of all 1,124,260 shares of the Company’s issued and outstanding Series D preferred stock, of its intention to redeem the Series D preferred stock on February 10, 2014 in accordance with the terms of the Certificate of Designations, Preferences and Rights of Series D Preferred Stock (the “Series D Certificate of Designations”). Following this notice, Pillar I had the right to convert its Series D preferred stock into shares of the Company’s common stock at any time prior to the close of business on February 9, 2014. On February 6, 2014, Pillar I converted such shares into 6,266,175 shares of the Company’s common stock in accordance with the terms of the Series D Certificate of Designations. As a result of the conversion, no shares of the Company’s Series D preferred stock remain outstanding.
	On March 28, 2014, the Company filed a Certificate of Elimination of Number of Shares of Preferred Stock Designated as Series D Convertible Preferred Stock with the State of Delaware Secretary of State which eliminated the designation of the shares of Series D preferred stock.
	Director Stock Purchases
	The Company issued 17,753 and 31,117 shares of common stock in lieu of director board and committee fees of approximately $62,000 and $18,000 pursuant to the Company’s director compensation program during the nine months ended September 30, 2014 and 2013, respectively.

Financing

Financing	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Financing	'
	(16) Financing
	Loan and Security Agreement
	On September 30, 2014, the Company executed a loan and security agreement with Oxford Finance LLC, (“Oxford”). Under the agreement, Oxford committed to lend the Company up to an aggregate principal amount of $3,000,000 in one or more advances each of which is to be evidenced by a promissory note. The Company’s obligations to Oxford will be secured by the specific laboratory, manufacturing, office or computer equipment financed under the agreement. Each equipment advance will include interest at a fixed interest rate equal to the greater of 7.5% per annum and 7.27% plus the three-month U.S. Libor Rate per annum, set at the time of funding. The principal amount of each equipment advance will be repaid in 36 monthly installments commencing on the applicable amortization date, which is July 1, 2015 for any equipment advance made on or before June 30, 2015, and is the first monthly payment date for any equipment advance made on or after July 1, 2015. Monthly installments payable prior to July 1, 2015 will consist of accrued interest only and monthly installments payable on or after July 1, 2015 will consist of principal and accrued interest.
	The Company is required to pay a final payment in an amount equal to 5.7% of the aggregate advanced amount under each equipment advance at the time that the final monthly installment is due or such earlier date as specified in the loan and security agreement. The final payments will be accrued as interest expense over the term of each equipment advance using the effective interest method. The weighted average annual effective interest rate on the notes payable based on the amount advanced through September 30, 2014, including accrual of the final payment, is 11.1%. If the Company prepays all or a portion of the principal amount of any equipment advance prior to maturity, it will be required to pay Oxford a prepayment fee of between 1% and 3% of the principal amount of such equipment advance.
	As of September 30, 2014, the Company had received approximately $893,000 in advances under the loan and security agreement and an additional $2,107,000 remained available under the agreement. Aggregate future minimum payments, reflecting payments on outstanding principal plus interest, due under the loan and security agreement as of September 30, 2014 were as follows (in thousands):
	Year ending December 31,
	2014	$	11
	2015		200
	2016		333
	2017		333
	2018		168
	Total minimum payments		1,045
	Less amount representing interest		(152	)
	Notes payable, gross		893
	Unamortized facility fee		(30	)
	Accrual of final payment		—
	Notes payable, balance		863
	Less current portion of notes payable		(59	)
	Non-current portion of notes payable	$	804
	The loan and security agreement includes standard affirmative and restrictive covenants, but does not include any covenants to attain or maintain any financial metrics, and also includes standard events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of Oxford’s security interest or in the value of the collateral, a material impairment of the prospect of repayment of the loans and a material adverse change in the business, operations or conditions of the Company. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and Oxford may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan and security agreement.
	10
	The Company assessed all terms and features of the Note Agreement in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the Note Agreement, including put and call features. The Company determined that all features of the Note Agreement are clearly and closely associated with a debt host and do not require bifurcation as a derivative liability, or the fair value of the feature is immaterial. The Company will continue to reassess the features to determine if they require separate accounting on a quarterly basis.
	February 10, 2014 Follow-on Underwritten Public Offering
	On February 10, 2014, the Company closed a follow-on underwritten public offering, in which it sold 7,867,438 shares of common stock at a price to the public of $4.00 per share and pre-funded warrants to purchase up to 2,158,750 shares of common stock at a price to the public of $3.99 per share for aggregate gross proceeds of $40.1 million. The pre-funded warrants have an exercise price of $0.01 per share and will expire if not exercised by February 10, 2021. The net proceeds to the Company from the offering, after deducting underwriters’ discounts and commissions and other offering costs and expenses and excluding the proceeds of the exercise of the warrants, if any, were approximately $37.2 million.
	September 30, 2013 Follow-on Underwritten Public Offering
	On September 30, 2013, the Company closed a follow-on underwritten public offering, in which it sold 13,727,251 shares of common stock at a price to the public of $1.55 per share and pre-funded warrants to purchase up to 4,175,975 shares of common stock at a price to the public of $1.54 per share for aggregate gross proceeds of $27.7 million. The pre-funded warrants have an exercise price of $0.01 per share and will expire if not exercised by September 30, 2020. The net proceeds to the Company from the offering, after deducting underwriters’ discounts and commissions and offering costs and expenses and excluding the proceeds of the exercise of the warrants, if any, were approximately $25.7 million.
	May 7, 2013 Follow-on Underwritten Public Offering
	On May 7, 2013, the Company closed a follow-on underwritten public offering, in which it sold 17,500,000 shares of common stock, together with matching warrants to purchase up to 17,500,000 shares of common stock, and pre-funded warrants to purchase up to 15,816,327 shares of common stock, together with matching warrants to purchase up to 15,816,327 shares of common stock, for aggregate gross proceeds of $16.5 million as follows:
		Combined Price			Common		Pre-funded		Matching
		to the Public			Stock		Warrants		Warrants
		(per share of
		common stock)
	Common stock and matching warrants sold (shares)	$	0.5			17,500,000		—		17,500,000
	Pre-funded warrants and matching warrants sold (shares)	$	0.49			—		15,816,327		15,816,327
	Total (shares)					17,500,000		15,816,327		33,316,327
	Warrant exercise price (per share)		—			—	$	0.01	$	0.47
	Term of warrant (years)		—			—		7		5
	The net proceeds to the Company from the offering, after deducting underwriters’ discounts and commissions and offering costs and expenses and excluding the proceeds of the future exercise of the warrants, if any, were approximately $14.5 million.
	The warrants and the pre-funded warrants each provide that, after the second anniversary of the date of issuance, the Company may redeem the warrants for $0.01 per share of common stock issuable on exercise of the warrants following 30 days’ prior written notice to the holder if the closing price of the common stock for 20 or more trading days in a period of 30 consecutive trading days is greater than or equal to $2.80.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	(17) Subsequent Events
	The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

New_Accounting_Pronouncements_1

New Accounting Pronouncements - Recently Issued (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
New Accounting Pronouncements - Recently Issued	'
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-08 — Presentation of Financial Statements (Topic 205) and Property, Plant, and Equipment (Topic 360): Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. The amendments in this ASU require that a disposal representing a strategic shift that has (or will have) a major effect on an entity’s operations and financial results or a business activity classified as held for sale should be reported as discontinued operations. The amendments also expand the disclosure requirements for discontinued operations and add new disclosure requirements for individually significant components that do not qualify as discontinued operations. This ASU will be effective prospectively for fiscal years beginning on or after December 15, 2014. Early adoption is permitted, but only for disposals that have not been previously reported in financial statements previously issued. The Company does not expect the adoption of this ASU to have a material effect on its financial statements.
	In May 2014, the FASB issued ASU No. 2014-09 — Revenue from Contracts with Customers (Topic 606). This ASU requires an entity to recognize revenue from the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In particular, this ASU addresses contracts with more than one performance obligation, as well as the accounting for some costs to obtain or fulfill a contract with a customer, and provides for additional disclosures with respect to revenues and cash flows arising from contracts with customers. This ASU will be effective for fiscal years beginning after December 15, 2016. Early adoption of this ASU is not permitted. The Company is currently evaluating the effect that the adoption of this ASU will have on its financial statements.

Fair_Value_of_Assets_and_Liabi1

Fair Value of Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Measured at Fair Value on a Recurring Basis	'
	The table below presents the assets and liabilities measured and recorded in the financial statements at fair value on a recurring basis at September 30, 2014 and December 31, 2013 categorized by the level of inputs used in the valuation of each asset and liability.
	(In thousands)	Total		Quoted Prices		Significant		Significant
				in Active		Other		Unobservable
				Markets		Observable		Inputs
				for Identical		Inputs		(Level 3)
				Assets or		(Level 2)
				Liabilities
				(Level 1)
	September 30, 2014
	Assets
	Money market funds	$	47,181	$	47,181	$	—	$	—
	Short-term investments — commercial paper		999		—		999		—
	Short-term investments — corporate bonds		8,790		—		8,790		—
	Total Assets	$	56,970	$	47,181	$	9,789	$	—
	(In thousands)	Total		Quoted Prices		Significant		Significant
				in Active		Other		Unobservable
				Markets		Observable		Inputs
				for Identical		Inputs		(Level 3)
				Assets or		(Level 2)
				Liabilities
				(Level 1)
	December 31, 2013
	Assets
	Money market funds	$	25,201	$	25,201	$	—	$	—
	Short-term investments — commercial paper		1,997		—		1,997		—
	Short-term investments — corporate bonds		1,128		—		1,128		—
	Long-term investments — corporate bonds		6,189		—		6,189		—
	Total Assets	$	34,515	$	25,201	$	9,314	$	—

Investments_Tables

Investments (Tables)	9 Months Ended
	Sep. 30, 2014
Investments, Debt and Equity Securities [Abstract]	'
Summary of Available-for-Sale Investments at Fair Value	'
	The Company’s available-for-sale investments at fair value consisted of the following at September 30, 2014 and December 31, 2013:
		September 30, 2014
		Cost		Gross			Gross		Estimated
				Unrealized			Unrealized		Fair Value
				(Losses)			Gains
		(In thousands)
	Short-term investments — commercial paper	$	999	$	—		$	—	$	999
	Short-term investments — corporate bonds		8,792		(3	)		1		8,790
	Total investments	$	9,791	$	(3	)	$	1	$	9,789
		December 31, 2013
		Cost		Gross			Gross		Estimated
				Unrealized			Unrealized		Fair Value
				(Losses)			Gains
		(In thousands)
	Short-term investments — commercial paper	$	1,997	$	—		$	—	$	1,997
	Short-term investments — corporate bonds		1,128		—			—		1,128
	Total short-term investments		3,125		—			—		3,125
	Long-term investments — corporate bonds		6,196		(7	)		—		6,189
	Total investments	$	9,321	$	(7	)	$	—	$	9,314

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Tabular Disclosure of Major Components of Property and Equipment and Related Accumulated Depreciation	'
	At September 30, 2014 and December 31, 2013, net property and equipment at cost consisted of the following:
	(In thousands)	September 30,		December 31,
		2014		2013
	Leasehold improvements	$	525	$	525
	Laboratory equipment and other		3,536		2,854
	Total property and equipment, at cost		4,061		3,379
	Less: accumulated depreciation		3,135		3,289
	Property and equipment, net	$	926	$	90

Comprehensive_Income_Loss_Tabl

Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Changes in Accumulated Balance of the Component of Other Comprehensive Gain (Loss)	'
	The following table includes the changes in the accumulated balance of the component of other comprehensive gain (loss) for the nine months ended September 30, 2014:
	(In thousands)	Nine Months
		ended September 30,
		2014
	Accumulated unrealized loss on available-for-sale securities at beginning of period	$	(7	)
	Change during the period		5
	Accumulated unrealized loss on available-for-sale securities at end of period	$	(2	)

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted During Period	'
	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions apply to the options to purchase 2,518,500 and 3,130,083 shares of common stock granted to employees and directors during the nine months ended September 30, 2014 and 2013, respectively:
		Nine Months Ended
		September 30,
		2014			2013
	Average risk free interest rate		1.6	%		1.3	%
	Expected dividend yield		—			—
	Expected lives (years)		4.8			5.2
	Expected volatility		83	%		62	%
	Weighted average grant date fair value of options granted during the period (per share)	$	2.47		$	0.49
	Weighted average exercise price of options granted during the period (per share)	$	3.8		$	0.92

Financing_Tables

Financing (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Schedule of Aggregate Future Minimum Payments Due Under Loan and Security Agreement	'
	Aggregate future minimum payments, reflecting payments on outstanding principal plus interest, due under the loan and security agreement as of September 30, 2014 were as follows (in thousands):
	Year ending December 31,
	2014	$	11
	2015		200
	2016		333
	2017		333
	2018		168
	Total minimum payments		1,045
	Less amount representing interest		(152	)
	Notes payable, gross		893
	Unamortized facility fee		(30	)
	Accrual of final payment		—
	Notes payable, balance		863
	Less current portion of notes payable		(59	)
	Non-current portion of notes payable	$	804
May 2013 Follow-on Underwritten Public Offering	'
	On May 7, 2013, the Company closed a follow-on underwritten public offering, in which it sold 17,500,000 shares of common stock, together with matching warrants to purchase up to 17,500,000 shares of common stock, and pre-funded warrants to purchase up to 15,816,327 shares of common stock, together with matching warrants to purchase up to 15,816,327 shares of common stock, for aggregate gross proceeds of $16.5 million as follows:
		Combined Price			Common		Pre-funded		Matching
		to the Public			Stock		Warrants		Warrants
		(per share of
		common
		stock)
	Common stock and matching warrants sold (shares)	$	0.5			17,500,000		—		17,500,000
	Pre-funded warrants and matching warrants sold (shares)	$	0.49			—		15,816,327		15,816,327
	Total (shares)					17,500,000		15,816,327		33,316,327
	Warrant exercise price (per share)		—			—	$	0.01	$	0.47
	Term of warrant (years)		—			—		7		5

Organization_Additional_Inform

Organization - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Accumulated deficit	($439,608)	($412,884)

Cash_and_Cash_Equivalents_Addi

Cash and Cash Equivalents - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Maximum period to maturity to be considered a cash equivalent	'90 days

Fair_Value_of_Assets_and_Liabi2

Fair Value of Assets and Liabilities - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (Fair Value, measurements, recurring [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	$56,970	$34,515
Money market funds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	47,181	25,201
Short-term investments - commercial paper [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	999	1,997
Short-term investments - corporate bonds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	8,790	1,128
Long-term investments - corporate bonds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	'	6,189
Quoted prices in active markets for identical assets or liabilities (Level 1) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	47,181	25,201
Quoted prices in active markets for identical assets or liabilities (Level 1) [Member] | Money market funds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	47,181	25,201
Significant other observable inputs (Level 2) [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	9,789	9,314
Significant other observable inputs (Level 2) [Member] | Short-term investments - commercial paper [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	999	1,997
Significant other observable inputs (Level 2) [Member] | Short-term investments - corporate bonds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	8,790	1,128
Significant other observable inputs (Level 2) [Member] | Long-term investments - corporate bonds [Member]	'	'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Total Assets	'	$6,189

Investments_Summary_of_Availab

Investments - Summary of Available-for-Sale Investments at Fair Value (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	$9,791	$9,321
Gross Unrealized (Losses)	-3	-7
Gross Unrealized Gains	1	'
Estimated Fair Value	9,789	9,314
Short-term investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	'	3,125
Estimated Fair Value	'	3,125
Short-term investments [Member] | Commercial paper [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	999	1,997
Estimated Fair Value	999	1,997
Short-term investments [Member] | Corporate bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	8,792	1,128
Gross Unrealized (Losses)	-3	'
Gross Unrealized Gains	1	'
Estimated Fair Value	8,790	1,128
Long-term investments [Member] | Corporate bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Cost	'	6,196
Gross Unrealized (Losses)	'	-7
Estimated Fair Value	'	$6,189

Investments_Additional_Informa

Investments - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'	'	'	'	'
Realized gains or losses from available-for-sale securities	'	'	$0	$0	'
Auction rate securities, noncurrent	0	'	0	'	0
Losses on investment	$0	$0	$0	$0	'

Property_and_Equipment_Tabular

Property and Equipment - Tabular Disclosure of Major Components of Property and Equipment and Related Accumulated Depreciation (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Abstract]	'	'
Leasehold improvements	$525	$525
Laboratory equipment and other	3,536	2,854
Total property and equipment, at cost	4,061	3,379
Less: accumulated depreciation	3,135	3,289
Property and equipment, net	$926	$90

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation and amortization expense	$57	$31	$135	$106

Restricted_Cash_Additional_Inf

Restricted Cash - Additional Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Restricted Cash [Abstract]	'	'
Total restricted cash	$311,000	$311,000

Collaborations_Additional_Info

Collaborations - Additional Information (Detail) (Abbott Molecular [Member], USD $)	1 Months Ended
	Sep. 30, 2014	31-May-14	Apr. 30, 2014
Abbott Molecular [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Paid or expects to pay for external development expenses	$1,808,000	$6,700,000	'
Expected agreement term	'	'5 years	'
Maximum amount that may be credited towards any amount due from collaborator for third-party license income received by the Company	'	'	$60,000,000
Percentage of third-party license income received by the Company that is credited towards any amount due from collaborator	'	'	15.00%

Comprehensive_Income_Loss_Chan

Comprehensive Income (Loss) - Changes in Accumulated Balance of the Component of Other Comprehensive Gain (Loss) (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Comprehensive Income Before Tax [Abstract]	'	'
Accumulated unrealized loss on available-for-sale securities at beginning of period	'	($7)
Change during the period	-5	5
Accumulated unrealized loss on available-for-sale securities at end of period	($2)	($2)

Comprehensive_Income_Loss_Addi

Comprehensive Income (Loss) - Additional Information (Detail) (USD $)	Sep. 30, 2013
Comprehensive Income Before Tax [Abstract]	'
Accumulated unrealized gain or loss on available-for-sale securities	$0

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Recorded charges in statement of operations	$766	$476	$2,086	$994
Options to purchase common stock granted to employees and directors	'	'	2,518,500	3,130,083
Employees [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock options vesting period	'	'	'4 years	'
Directors [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock options vesting period	'	'	'3 years	'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted During Period (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Average risk free interest rate	1.60%	1.30%
Expected dividend yield	'	'
Expected lives (years)	'4 years 9 months 18 days	'5 years 2 months 12 days
Expected volatility	83.00%	62.00%
Weighted average grant date fair value of options granted during the period (per share)	$2.47	$0.49
Weighted average exercise price of options granted during the period (per share)	$3.80	$0.92

Net_Loss_per_Common_Share_Appl1

Net Loss per Common Share Applicable to Common Stockholders - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Total antidilutive securities	'	'	78,349,485	87,624,124
Preferred stock dividends	$119,000	$278,000	$422,000	$2,587,000
Series E preferred stock [Member]	'	'	'	'
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Preferred stock dividends	119,000	'	'	'
Series D and E preferred stock [Member]	'	'	'	'
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Preferred stock dividends	'	278,000	422,000	837,000
Loss on extinguishment of convertible preferred stock	'	'	'	$1,750,000
Series D preferred stock [Member]	'	'	'	'
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]	'	'	'	'
Preferred stock conversion date	'	'	6-Feb-14	'

Common_Stock_Warrant_and_Optio1

Common Stock Warrant and Option Exercises and Employee Stock Purchases - Additional Information (Detail) (Common Stock Warrant And Option Exercises And Employee Stock Purchases [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Common Stock Warrant And Option Exercises And Employee Stock Purchases [Member]	'	'
Employee Stock Option And Warrant Exercises And ESPP Purchases [Line Items]	'	'
Number of shares of common stock issued for stock warrant and stock options exercised and ESPP purchases	5,398,609	3,780,945
Proceeds from stock issued for warrant and option exercises & ESPP purchases	$8,132,000	$1,864,000

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	9 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Feb. 06, 2014	Sep. 30, 2014	Feb. 10, 2014	Feb. 06, 2014	Dec. 31, 2013
			Series D preferred stock [Member]	Series D preferred stock [Member]	Series D preferred stock [Member]	Series D preferred stock [Member]	Series D preferred stock [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'
Preferred stock, shares issued	'	'	'	0	1,124,260	'	1,124,000
Preferred stock, shares outstanding	'	'	'	0	1,124,260	'	1,124,000
Shares of common stock issued upon conversion of Series D preferred stock	'	'	6,266,175	'	'	'	'
Number of shares of Series D Preferred Stock outstanding after conversion	'	'	'	'	'	0	'
Common stock issued in lieu of board fees	17,753	31,117	'	'	'	'	'
Common stock issued	$62,000	$18,000	'	'	'	'	'

Financing_Additional_Informati

Financing - Additional Information (Detail) (Oxford [Member], USD $)	9 Months Ended
	Sep. 30, 2014
	Installment
Oxford [Member]	'
Debt Instrument [Line Items]	'
Borrowing capacity under the Loan & security agreement	$3,000,000
Basis spread on fixed interest rate set at time of advance	7.27%
Minimum interest rate	7.50%
Description of interest rate	'Each equipment advance will include interest at a fixed interest rate equal to the greater of 7.5% per annum and 7.27% plus the three-month U.S. Libor Rate per annum
Debt instrument payment terms	'The principal amount of each equipment advance will be repaid in 36 monthly installments commencing on the applicable amortization date, which is July 1, 2015 for any equipment advance made on or before June 30, 2015, and is the first monthly payment date for any equipment advance made on or after July 1, 2015. Monthly installments payable prior to July 1, 2015 will consist of accrued interest only and monthly installments payable on or after July 1, 2015 will consist of principal and accrued interest
Debt instrument number of installments that include principal payable	36
Final payment of additional interest as a percentage of aggregate amount advanced	5.70%
Weighted average annual effective interest rate	11.10%
Minimum prepayment fee interest rate percentage	1.00%
Maximum prepayment fee interest rate percentage	3.00%
Advance received under loan and security agreement	893,000
Amount available for borrowing under agreement	$2,107,000
Outstanding loan balance, default interest rate	5.00%

Financing_Schedule_of_Aggregat

Financing - Schedule of Aggregate Future Minimum Payments Due Under Loan and Security Agreement (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Debt Instruments [Abstract]	'
2014	$11
2015	200
2016	333
2017	333
2018	168
Total minimum payments	1,045
Less amount representing interest	-152
Notes payable, gross	893
Unamortized facility fee	-30
Accrual of final payment	'
Notes payable, balance	863
Notes payable, balance	863
Less current portion of notes payable	-59
Non-current portion of notes payable	$804

Financing_Additional_Informati1

Financing - Additional Information 1 (Detail) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 10, 2014	Sep. 30, 2013	7-May-13	Feb. 10, 2014	Sep. 30, 2013
Class of Stock [Line Items]	'	'	'	'	'
Common stock sold	'	13,727,251	'	'	'
Gross proceeds from sale of common stock and warrants excluding the proceeds from exercise of the warrants, if any	$40.10	$27.70	$16.50	'	'
Price to the public per share of common stock	'	$1.55	'	'	'
Sales price per share of prefunded warrants	'	'	'	$3.99	$1.54
Estimated net proceeds from sale of common stock and warrants excluding the proceeds from exercise of the warrants, if any	$37.20	$25.70	'	'	'
Common Stock [Member]	'	'	'	'	'
Class of Stock [Line Items]	'	'	'	'	'
Common stock sold	7,867,438	'	'	'	'
Price to the public per share of common stock	$4	'	'	'	'
Pre-funded warrants [Member]	'	'	'	'	'
Class of Stock [Line Items]	'	'	'	'	'
Shares of common stock that may be purchased upon exercise of the warrants	'	'	15,816,327	2,158,750	4,175,975
Warrant exercise price (per share)	'	'	$0.01	$0.01	$0.01
Pre-funded warrants expiration date	10-Feb-21	30-Sep-20	'	'	'

Financing_Additional_Informati2

Financing - Additional Information 2 (Detail) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 10, 2014	Sep. 30, 2013	7-May-13	Feb. 10, 2014	Sep. 30, 2013
Class of Stock [Line Items]	'	'	'	'	'
Common stock sold	'	13,727,251	'	'	'
Gross proceeds from sale of common stock and warrants excluding the proceeds from exercise of the warrants, if any	$40.10	$27.70	$16.50	'	'
Price to the public per share of common stock	'	$1.55	'	'	'
Sales price per share of prefunded warrants	'	'	'	$3.99	$1.54
Estimated net proceeds from sale of common stock and warrants excluding the proceeds from exercise of the warrants, if any	$37.20	$25.70	'	'	'
Pre-funded warrants [Member]	'	'	'	'	'
Class of Stock [Line Items]	'	'	'	'	'
Shares of common stock that may be purchased upon exercise of the warrants	'	'	15,816,327	2,158,750	4,175,975
Warrant exercise price (per share)	'	'	$0.01	$0.01	$0.01
Pre-funded warrants expiration date	10-Feb-21	30-Sep-20	'	'	'

Financing_Additional_Informati3

Financing - Additional Information 3 (Detail) (USD $)	0 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 10, 2014	Sep. 30, 2013	7-May-13
Class of Stock [Line Items]	'	'	'
Common stock sold	'	13,727,251	'
Gross proceeds from sale of common stock and warrants excluding the proceeds from exercise of the warrants, if any	$40.10	$27.70	$16.50
Pre-funded warrants [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Issuance of warrants to purchase shares common stock	'	'	15,816,327
Common Stock [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Common stock sold	'	'	17,500,000
Matching Warrants [Member] | Pre-funded warrants [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Issuance of warrants to purchase shares common stock	'	'	15,816,327
Matching Warrants [Member] | Common Stock [Member]	'	'	'
Class of Stock [Line Items]	'	'	'
Issuance of warrants to purchase shares common stock	'	'	17,500,000

Financing_May_2013_Followon_Un

Financing - May 2013 Follow-on Underwritten Public Offering (Detail) (USD $)	0 Months Ended
	7-May-13	Feb. 10, 2014	Sep. 30, 2013	7-May-13
Common Stock [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Number of shares of common stock sold in financing	17,500,000	'	'	'
Common Stock and Matching Warrants Sold [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Combined price to the public per share of common stock	$0.50	'	'	$0.50
Common Stock and Matching Warrants Sold [Member] | Common Stock [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Number of shares of common stock sold in financing	17,500,000	'	'	'
Pre-funded Warrants & Matching Warrants Sold [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Combined price to the public per share of common stock	$0.49	'	'	$0.49
Matching Warrants [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Total (shares)	'	'	'	33,316,327
Warrant exercise price (per share)	'	'	'	$0.47
Term of warrant (years)	'5 years	'	'	'
Matching Warrants [Member] | Common Stock and Matching Warrants Sold [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Total (shares)	17,500,000	'	'	17,500,000
Matching Warrants [Member] | Pre-funded Warrants & Matching Warrants Sold [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Total (shares)	15,816,327	'	'	15,816,327
Pre-funded warrants [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Total (shares)	'	2,158,750	4,175,975	15,816,327
Warrant exercise price (per share)	'	$0.01	$0.01	$0.01
Term of warrant (years)	'7 years	'	'	'
Pre-funded warrants [Member] | Pre-funded Warrants & Matching Warrants Sold [Member]	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Total (shares)	15,816,327	'	'	15,816,327

Financing_Additional_Informati4

Financing - Additional Information 4 (Detail) (USD $)	0 Months Ended
In Millions, unless otherwise specified	7-May-13	7-May-13
Equity [Abstract]	'	'
Net proceeds from sale of common stock and warrants excluding the proceeds from future exercise of the warrants, if any	$14.50	'
Redemption price per share of warrants	0.01	'
Notice period to holder prior to redemption of warrants by Company	'30 days	'
Minimum trading days considered to redeem warrants	'20 days	'
Maximum trading days considered to redeem warrants	'30 days	'
Minimum closing price to redeem the warrants	'	2.8